October 29, 2025 — Leads & Copy — Savara Inc. (Nasdaq: SVRA) has entered into a $75 million royalty funding agreement with RTW Investments, LP, pending FDA approval of MOLBREEVI, to support its U.S. launch and commercial priorities.
Matt Pauls, J.D., M.B.A., Chair and CEO of Savara, expressed confidence in MOLBREEVI’s potential to transform the treatment of autoimmune PAP, a rare and chronic disease with no approved medicines in the U.S. and Europe.
Roderick Wong, M.D., Managing Partner and CIO of RTW Investments, LP, cited the IMPALA-2 clinical trial’s promising results as a basis for their investment, reflecting confidence in Savara and MOLBREEVI’s commercial potential.
The royalty financing is contingent on FDA approval of MOLBREEVI and other customary conditions, with RTW receiving a tiered single-digit percentage of MOLBREEVI’s annual net sales in the U.S., subject to a cap.
Autoimmune PAP is a rare lung disease marked by surfactant buildup, impairing gas transfer and leading to symptoms like shortness of breath and fatigue. Savara’s MOLBREEVI aims to address this unmet need.
Matt Pauls, J.D., M.B.A., Chair and Chief Executive Officer, Savara.
Source: Savara Inc.
